anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To allay a pain and treat a burn and a water blister by employing an organism and cells. CONSTITUTION:An organism and cells are employed to treat a pain. A juice prepared by squeezing the organism is coated on the skin. On the living leaf of the organism or the leaf dried in the shade is employed. The leaf dried in the shade is recovered in water and adhered to a pain position. The employment of the organism permits the rapid treatment and exhibits a good effect ever when coated once. The employment allows the pain within an hour when rapid, but usually within 12 hours. The employment method is simple and permits to exhibit the effect rapidly, and the ingredient of the organism is transferred into the body by the force of the cells to strengthen the weekened cells.
BACKGROUND: As nucleos/tide analogue (NA) therapy (e.g. entecavir and tenofovir) for chronic Hepatitis B virus (HBV) infection becomes more widely indicated and available, understanding drug resistance is essential. A systematic review to quantify resistance to these agents has not previously been undertaken.
METHODS: We performed a systematic review and random-effects meta-analysis to estimate the risk of HBV resistance to entecavir and tenofovir. We searched nine databases up to 29-Aug-23. We included studies of HBV infection featuring >10 individuals, written in English, reporting treatment ≥48 weeks, with assessment of HBV resistance based on viral sequence data. Data were analysed according to prior exposure history to NA, and choice of NA agent. Analyses were performed in R.
FINDINGS: 62 studies involving a total of 12,358 participants were included. For entecavir, in treatment-naive individuals (22 studies; 4326 individuals), resistance increased over time to 0.9 % at ≥5 years (95 %CI 0.1-2.3 %), and resistance was increased in NA-experienced individuals (18 studies; 1112 individuals), to 20.1 % (95 %CI 1.6-50.1 %) at ≥5 years. For tenofovir, pooled resistance risk was 0.0 % at all time points, whether previously NA naive (11 studies; 3778 individuals) or experienced (19 studies; 2059 individuals). There was a lack of consistent definitions, poor global representation and insufficient metadata to support subgroup analysis.
INTERPRETATION: We have generated the first pooled estimates of HBV entecavir and tenofovir resistance over time. HBV resistance to entecavir in treatment-experienced groups in particular may represent a clinical and public health challenge. To date, tenofovir appears to have an excellent resistance profile, but due to data gaps, we caution that existing studies under-estimate the true real-world risk of resistance. Robust prospective data collection is crucial to reduce health inequities and reduce blind-spots in surveillance as treatment is rolled out more widely.
BACKGROUND: Macrophage polarisation-mediated inflammation plays a critical role in ventricular remodelling after myocardial infarction (MI). Sacubitril/Valsartan (Sac/Val) is an angiotensin receptor-neprilysin inhibitor that has shown beneficial effects on MI and heart failure. This study aims to further explore the mechanisms by which Sac/Val exerts its protective effects against MI.
METHODS: A mouse MI model was induced by ligating the left anterior descending coronary artery, followed by Sac/Val administration. TTC staining and Masson trichrome staining were employed for estimating myocardial infarct size and fibrosis, respectively. The expression levels of proinflammatory factors were determined by ELISA and RT-qPCR. Flow cytometry and immunofluorescence staining were implemented to detect CD206-positive cell infiltration in mouse hearts. Western blotting was conducted to assess protein levels of Arg1, pro-fibrotic factors, and PI3K/Akt signalling-related markers.
RESULTS: Sac/Val treatment reduced myocardial infarct size and fibrosis in mice after MI. Sac/Val administration decreased proinflammatory cytokine production and facilitated M2 macrophage polarisation in MI mouse cardiac tissues. Sac/Val activated PI3K/Akt signalling in MI mouse hearts. Blocking PI3K/Akt signalling counteracted Sac/Val-mediated protective effects in MI mice.
CONCLUSION: Sac/Val ameliorates MI-induced inflammation by facilitating M2 macrophage polarisation and activating PI3K/Akt signalling.
Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.
A solution suitable for the treatment of hair comprises a mixture in water and methyl, ethyl, propyl, or isopropyl alcohol of a carboxylcontaining polymer in which a substantial proportion of the acid groups are neutralized with an amine containing an alkyl group of C10 to C20 carbon atoms, and the remainder or part thereof are neutralized by salt formation with water-soluble alkaline substance. The carboxyl-containing polymer may be polymethacrylic acid or a partially hydrolysed polymethyl methacrylate or the polymers described in Specifications 575,512, 799,200, and 799,951.  The solutions may also contain tinting colours and perfumes.  The alkylamine may be dodecylamine, di-dodecylamine, or tri-dodecylamine. The alkaline substance may be an alkali hydroxide a-mono,- di- or tri-ethanolamine, or ammonia.ALSO:A toilet preparation suitable for conditioning and/or assisting in the setting of hair comprises an alginic acid or a carboxly-containing polymer in which a substantial proportion of the acid groups are neutralised with an amine containing an alkyl group of C10 to C20 carbon atoms, and the remainder or a part thereof are neutralized by salt formation with a water-soluble alkaline substance, dissolved in water and methyl, ethyl, propyl or isopropyl alcohol.  The solution may also contain tinting colours and perfumes.  The carboxyl-containing polymer may be polymethacrylic acid or a partially hydrolysed polymethyl methacrylate or a polymer described in Specifications 575,512, 799,200, and 799,951.  The alkylamine may be dodecylamine, didodecylamine, or tri-dodecylamine.  The alkaline substance may be an alkali hydroxide, a mono-di- or triethanolamine, or ammonia.
PCT No. PCT/GB96/02156 Sec. 371 Date May 8, 1998 Sec. 102(e) Date May 8, 1998 PCT Filed Sep. 2, 1996 PCT Pub. No. WO97/09036 PCT Pub. Date Mar. 13, 1997A process is provided for preparing a granular pharmnaceutical ion exchange resin composition that is readily dispersible in water by granulating an ion exchange resin, having a pharmacologically active ingredient bound thereto, with a particulate sugar or sugar alcohol. The process is characterised by the use of an aqueous solution of a sugar or sugar alcohol as a granulating medium.
The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly a type 2 inflammatory disease associated with type 2 (T2) cell responses and epithelial barrier, mucociliary, and olfactory dysfunction. The inflammatory cytokines interleukin (IL)-4, IL-13, and IL-5 are key mediators driving and perpetuating type 2 inflammation. The inflammatory responses driven by these cytokines include the recruitment and activation of eosinophils, basophils, mast cells, goblet cells, M2 macrophages, and B cells. The activation of these immune cells results in a range of pathologic effects including immunoglobulin E production, an increase in the number of smooth muscle cells within the nasal mucosa and a reduction in their contractility, increased deposition of fibrinogen, mucus hyperproduction, and local edema. The cytokine-driven structural changes include nasal polyp formation and nasal epithelial tissue remodeling, which perpetuate barrier dysfunction. Type 2 inflammation may also alter the availability or function of olfactory sensory neurons contributing to loss of sense of smell. Targeting these key cytokine pathways has emerged as an effective approach for the treatment of type 2 inflammatory airway diseases, and a number of biologic agents are now available or in development for CRSwNP. In this review, we provide an overview of the inflammatory pathways involved in CRSwNP and describe how targeting key drivers of type 2 inflammation is an effective therapeutic option for patients.
BACKGROUND: Motion sickness, is the onset of a series of clinical signs when travelling in a means of locomotion. Boats are the most common source of kinetosis, causing seasickness. Although this condition is often benign, it can severely affect the quality of life of seafarers, as well as the quality of their work. The aim of this study is to focus on the point prevalence and characteristics of seasickness in a population of French civilian seafarers from all shipping sectors.
MATERIALS AND METHODS: During two months in 2023, we conducted a cross-sectional study based on a questionnaire containing 28 questions.
RESULTS: One hundred nine men and 10 women completed the questionnaire. Of these, 34% said they were seasick. The main symptoms described by the sailors were nausea and cold sweats in 87.5% and 50% of cases, respectively. The prevalence of naupathy appears to be higher in women (60% compared with 31% in men). Women also seem to be less accustomed to the marine environment than men, with 71% of men and only 33% of women indicating that they get accustomed to life at sea. However, the symptoms of seasickness seem to disappear more slowly in men than in women. In terms of treatment, men (38%) were more likely to take medication than women (17%).
CONCLUSIONS: Our study shows a greater susceptibility to seasickness among women. This interpretation should be treated with caution given the small number of women who took part in the study. The relatively low point prevalence of seasickness (34%) could be due to under-reporting. Although ways of thinking are changing, seasickness is still a taboo subject for many sailors. Yet seasickness has major professional and personal repercussions. So it's important to raise the subject and discuss strategies for improving well-being at work.
APOKYN (apomorphine hydrochloride injection) contains apomorphine hydrochloride, a non-ergoline dopamine agonist. Apomorphine hydrochloride is chemically designated as 6aβ-Aporphine-10,11-diol hydrochloride hemihydrate with a molecular formula of C 17H 17NO 2 ∙ HCl ∙ ½ H 2O. Its structural formula and molecular weight are: 

Apomorphine hydrochloride appears as minute, white or grayish-white glistening crystals or as white powder that is soluble in water at 80°C.

APOKYN is a clear, colorless, sterile solution for subcutaneous injection and is available in 3 mL (30 mg) multi-dose cartridges. Each mL of solution contains 10 mg of apomorphine hydrochloride, USP as apomorphine hydrochloride hemihydrate (equivalent to 8.55 mg apomorphine), 1 mg of sodium metabisulfite, NF and 5 mg of benzyl alcohol, NF (preservative) in water for injection, USP. In addition, each mL of solution may contain sodium hydroxide, NF and/or hydrochloric acid, NF to adjust the pH of the solution.
A two- stage Simon Phase II study will be conducted in each of two groups of patients: related and unrelated donor transplants. In each donor transplant group, the first stage of this design will include 11 patients evaluated for death or graft failure by 100 days post-transplant. In each stratum, we will enroll additional patients (up to 20%) of stratum total to take into account exclusions due to donor failure (such as donor deemed unsuitable for stem cell donation due to medical or other reasons) only. Those patients who have toxicities related to Ruxolitinib and not been able to reach HCT due to these toxicities will be included in the estimation of overall failure rates. Only those patients who are excluded based on donor related issues without any regimen related complications will be excluded from the estimation of failure rates. However, all data on these patients will be reported.
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats. In laboratory animals, no anticholinergic or alpha1-adrenergic-receptor blocking effects were observed. Moreover, no sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.

Pseudoephedrine hydrochloride is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine hydrochloride is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.
During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
PURPOSE:A composition, prepared by incorporating an aqueous solution containing a polysaccharide, sucrose ester of a fatty acid and polyhydroxy compound with an oily substance or further with water, and having improved stability without irritation to the skin in the form of a cosmetic or hydrophilic ointment, etc. having improved luster. CONSTITUTION:An oil-in-water type emulsified composition prepared by incorporating a system consisting of (A) 0.01-1.5wt% polysaccharide, (B) 0.1-6.0wt% sucrose ester of a fatty acid and (C) 1.0-30.0wt%, expressed in terms of an anhydrous substance, polyhydroxy compound and 3.0-40wt% water with an oily substance or further water. A water-soluble polysaccharide, e.g. polysaccharide produced by microorganisms, seed polysaccharide, resin polysaccharide, seaweed polysaccharide, fruit polysaccharide, etc. is used as the component (A), and a surose ester of the fatty acid having 5.0-16.0 HLB is used as the component (B). An alkylene glycol, glycerol polyalkylene oxide, sugar alcohol, etc. is used as the component (C).
Prodn. of body-compatible tissue for treating or curing parodontosis comprises (i) implanting a solid foreign body (I) in a human or animal body; (ii) retaining (I) in the body for less than 50 (pref. 7-20, esp. 10) days; (iii) removing (I) together with the newly formed tissue capsule; and (iv) using the capsule tissue, opt. together with (I), fo treating or healing parodontosis. USE - The capsule tissue is surgically applied to the tooth pocket and fixed with a surgical suture or adhesive, to provide reattachment or fresh attachment of connective tissue and new cement and bone formation. (I) may also be a drug carrier.
Risk Summary

There are no data on the presence of ruxolitinib in human milk, the effects on the breastfed child, or the effects on milk production. Ruxolitinib was present in the milk of lactating rats (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the serious adverse findings in adults, including risks of serious infections, thrombocytopenia, anemia, and neutropenia, advise women not to breastfeed during treatment with OPZELURA and for approximately four weeks after the last dose (approximately 5-6 elimination half-lives). 

Data

Lactating rats were administered a single dose of [14C]-labeled ruxolitinib (30 mg/kg) on postnatal Day 10, after which plasma and milk samples were collected for up to 24 hours. The AUC for total radioactivity in milk was approximately 13 times the maternal plasma AUC. Additional analysis showed the presence of ruxolitinib and several of its metabolites in milk, all at levels higher than those in maternal plasma.
The invention discloses a formula used for treating qi stagnation. Qi stagnation is caused by weakness, lack of qi and blood, and climate change, and generally breaks out at autumn. People above 65 with low blood pressure are predisposed to qi stagnation. When qi stagnation breaks out, arthralgia is severe, swelling pain of enterocoelia moves, belly would swells like a drum, and patients are in great pain. Injection, transfusion and electrotherapy have no efficacy, and only the formula can be used to alleviate the pain. The formula comprises 3 portions of inula flower, 3 portions of cynanchum glaucescens, 3 portions of ochre, 3 portions of codonopsis pilosula, 2 portions of honey-fried licorice root, 3 portions of pinellia ternate, 3 portions of ginger, and 2 portions of jujube. The ingredients above are simmered. Inula flower, cynanchum glaucescens and pinellia ternate have efficacy of depressing qi and reducing phlegm; ochre has efficacy of decreasing inverse qi, and codonopsis pilosula, jujube, honey-fried licorice root and ginger has efficacy of nourishing healthy qi and yang; so that the formula is capable of enabling qi and blood to flow naturally. The formula which can be used to preventing qi stagnation is composed of the ingredients.
Chronic diarrhea presents a significant challenge for managing nutritional and electrolyte deficiencies, especially in children, given the higher stakes of impacting growth and developmental consequence. Congenital secretory diarrhea (CSD) compounds this further, particularly in the case of the activating variants of the guanylate-cyclase 2C (GUCY2C) gene. GUCY2C encodes for the guanylate-cyclase 2C (GC-C) receptor that activates the downstream cystic fibrosis transmembrane receptor (CFTR) that primarily drives the severity of diarrhea with an unclear extent of influence on other intestinal channels. Thus far, management for CSD primarily consists of mitigating nutritional, electrolyte, and volume deficiencies with no known pathophysiology-driven treatments. For activating variants of GUCY2C, experimental compounds have shown efficacy in vitro for direct inhibition of GC-C but are not currently available for clinical use. However, Crofelemer, a CFTR inhibitory modulator with negligible systemic absorption, can theoretically help to treat this type of CSD. Herein, we describe and characterize the clinical course of a premature male infant with a de novo missense variant of GUCY2C not previously reported and highly consistent with CSD. With multi-disciplinary family-directed decision-making, a treatment for CSD was evaluated for the first time to our knowledge with Crofelemer.
A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is γ-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.
MARGENZA can cause infusion-related reactions (IRRs) [see Adverse Reactions (6.1)]. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.

In SOPHIA, IRRs were reported by 13% of patients on MARGENZA plus chemotherapy. Most of the IRRs occur during Cycle 1. Grade 3 IRRs were reported in 1.5% of MARGENZA-treated patients. All IRRs resolved within 24 hours, irrespective of severity. In SOPHIA, IRRs leading to interruption of treatment occurred in 9% of patients treated with MARGENZA and chemotherapy. One patient (0.4%) on MARGENZA discontinued treatment due to IRR.

An infusion substudy in 88 patients in SOPHIA evaluated MARGENZA administered over 120 minutes for the initial dose, then 30 minutes from Cycle 2 forward. IRRs were ≤ Grade 2 and most occurred during the first (120 minutes) administration of MARGENZA. From Cycle 2 onward, one patient (1.1%) had an IRR (Grade 1). 

Monitor patients for IRRs during MARGENZA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use. Monitor patients carefully until resolution of signs and symptoms.

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. Decrease the rate of infusion for mild or moderate IRRs. Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.
Patients with psychotic disorders frequently require treatment at inpatient hospital settings during periods of acute illness for crisis management and stabilization. Although these patients often receive efficacious pharmacotherapy, there is a recognized lack of empirically-supported psychosocial interventions provided to patients in typical hospital settings. The provision of high quality psychosocial treatment during hospitalization is challenging due to short lengths of stay and a general lack of trained therapist employed on hospital units who can provide these evidence-based therapies. This unmet need for hospital psychosocial treatment represents a crucial missed opportunity to teach patients coping strategies that can speed time to recovery and impact post-discharge risk factors. Acceptance and Commitment Therapy (ACT) is a newer cognitive-behavioral approach that combines innovative mindfulness-based strategies for helping patients to cope more successfully with psychotic and other symptoms and implement values-consistent behavioral goals. However, adaptations to the original ACT approach are urgently needed to foster widespread implementation in community settings. The aim of the current study is to adapt the only promising acute-care psychosocial treatment for psychosis to be implementable in an inpatient setting and pilot test its effectiveness.
FIELD: veterinary virology. SUBSTANCE: medicinal agent has an active component in nutrient medium 199 - viruses of taxonomic group ECHO of strains ECHO-1 or ECHO-12. Effective amount of viruses is 5 lg TCD/0.5 ml. Stabilizing agent - gelatin-sucrose mixture at amount to 10% of total volume. Agent suppressing the growth of microbe-contaminants - antibiotic, for example, kanamycin sulfate at amount 0.01% of total volume of medicinal agent. Medicinal agent is administrated in animal organism by two-, four- or six-fold aerosol spraying, or peroral, or parenteral route at alternation of agent composition where an active component - viruses of strain ECHO-1 with that where an active component - viruses of strain ECHO-12. EFFECT: enhanced effectiveness of agent.